The failed clinical studies for relaxin-based treatments in SSc patients [12] may be related to reduced expression of RXFP1 in fibroblasts of these patients, which would abrogate their responsiveness to relaxin [14, 17–19]. Here, RXFP1 is linked to systemic sclerosis.